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The Coronavirus Disease 2019 (COVID-19) immuniza-tion program in the United Kingdom (UK) recommends COVID-19 vaccination for adults aged 18 and over. An inde-
pendent UK-wide body, the Joint Committee on Vaccination and 
Immunisation (JCVI), has recommended vaccination of all adults 
beginning with those at highest risk of serious COVID-19 out-
comes—in particular, hospitalizations and deaths (Supplementary 
Table 1)1. The three vaccines currently being administered in 
the UK—ChAdOx1 nCoV-19 (Oxford–AstraZeneca, hereaf-
ter ChAdOx1), BNT162b2 mRNA (Pfizer–BioNTech, hereafter 
BNT162b2) and mRNA-1273 (Moderna)—have been shown to 
reduce COVID-19 infections, hospitalizations and deaths2–5. Given 
that the first dose of mRNA-1273 was given in Scotland only on 7 
April 2021, this article will focus on ChAdOx1 and BNT162b2.
The risk of adverse events after vaccine administration has 
been assessed in clinical trials. These found that the ChAdOx1 and 
BNT162b2 vaccines have been generally well tolerated6,7. The most 
commonly reported adverse events included injection site reactions, 
such as pain, redness, tenderness and swelling, and non-serious 
systemic reactions, such as myalgia, headache, nausea and fever6–8. 
Reports of serious adverse events have been rare9. However, con-
cerns have been raised over the safety of the ChAdOx1 vaccine, and 
this has resulted in several countries initially temporarily suspend-
ing and then restricting use of ChAdOx1 to certain age groups10–13. 
By 4 April 2021, the European Medicines Agency (EMA) had 
received 169 reports of central venous thromboembolic events14,15, 
and an EMA signal assessment report on 8 April 2021 concluded 
that a signal of disproportionality was noted for rare events, such 
as disseminated intravascular coagulation, cerebral venous sinus 
thrombosis (CVST), as well as arterial thromboembolic and hem-
orrhagic stroke, which warranted further investigation16. The UK’s 
Medicines & Healthcare products and Regulatory Agency (MHRA) 
had received, as of 21 April 2021, 209 reports of thrombocytopenic 
and thromboembolic cases, after 22 million first doses and 6.8 mil-
lion second doses of the ChAdOx1 vaccine17. Three separate case 
series have described patients who developed thrombocytopenic 
and thrombotic events after ChAdOx1 vaccination, which clini-
cally mimics heparin-induced thrombocytopenia11–13. ChAdOx1’s 
summary of product characteristics has now been updated accord-
ingly. The JCVI has recommended that 18–39-year-old individuals 
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Reports of ChAdOx1 vaccine–associated thrombocytopenia and vascular adverse events have led to some countries restricting 
its use. Using a national prospective cohort, we estimated associations between exposure to first-dose ChAdOx1 or BNT162b2 
vaccination and hematological and vascular adverse events using a nested incident-matched case-control study and a confir-
matory self-controlled case series (SCCS) analysis. An association was found between ChAdOx1 vaccination and idiopathic 
thrombocytopenic purpura (ITP) (0–27 d after vaccination; adjusted rate ratio (aRR) = 5.77, 95% confidence interval (CI), 
2.41–13.83), with an estimated incidence of 1.13 (0.62–1.63) cases per 100,000 doses. An SCCS analysis confirmed that this 
was unlikely due to bias (RR = 1.98 (1.29–3.02)). There was also an increased risk for arterial thromboembolic events (aRR = 
1.22, 1.12–1.34) 0–27 d after vaccination, with an SCCS RR of 0.97 (0.93–1.02). For hemorrhagic events 0–27 d after vaccination, 
the aRR was 1.48 (1.12–1.96), with an SCCS RR of 0.95 (0.82–1.11). A first dose of ChAdOx1 was found to be associated with 
small increased risks of ITP, with suggestive evidence of an increased risk of arterial thromboembolic and hemorrhagic events. 
The attenuation of effect found in the SCCS analysis means that there is the potential for overestimation of the reported results, 
which might indicate the presence of some residual confounding or confounding by indication. Public health authorities should 
inform their jurisdictions of these relatively small increased risks associated with ChAdOx1. No positive associations were seen 
between BNT162b2 and thrombocytopenic, thromboembolic and hemorrhagic events.
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who do not have an underlying health condition should be offered 
an alternative to ChAdOx1, if available18,19. There have also been 
reports of post-vaccination exacerbation of chronic idiopathic or 
immune thrombocytopenic purpura among individuals receiving 
mRNA vaccines (including BNT162b2)20–22.
Given ongoing public, professional and regulatory concerns 
and the limited body of population-based evidence, there is an 
urgent need for evidence on the safety of all COVID-19 vaccines 
and, in particular, any association between COVID-19 vaccines 
and ITP and venous thromboembolic (including CVST) and arte-
rial thromboembolic and hemorrhagic events. To investigate this, 
we used a national prospective COVID-19 surveillance cohort in 
Scotland, which consisted of linked databases containing individual 
patient-level data relating to vaccination status, virological reverse 
transcription polymerase chain reaction (RT–PCR) COVID-19, 
laboratory tests and clinical and mortality records covering 5.4 mil-
lion people (~99% of the Scottish population).
Results
Between 8 December 2020 and 14 April 2021, 2.53 million people 
(57.5% of the adult population aged ≥18 years) received first doses 
of COVID-19 vaccines in Scotland. Of these, 1.71 milion people 
were vaccinated with the ChAdOx1 vaccine, and 0.82 million people 
were vaccinated with the BNT162b2 vaccine (Extended Data Fig. 1), 
with fewer than 10,000 people receiving the mRNA-1273 vaccine.
Thrombocytopenic events. For thrombocytopenia events (exclud-
ing ITP), the aRR in the period 0–27 d after vaccination for 
ChAdOx1 vaccination was 1.42 (95% CI, 0.86–2.37). There was evi-
dence of an increased risk of events 0–6 d after vaccination (aRR 
= 2.80, 95% CI, 1.39–5.67) (Table 1). In the adult population, the 
difference in expected versus observed events for thrombocytope-
nia was 1.33 (95% CI, −0.34–2.97) per 100,000 doses. The SCCS 
analysis, used as a post hoc analysis to investigate confounding by 
indication, for ChAdOx1 and thrombocytopenia (excluding ITP) 
found an RR of 1.07 (95% CI, 0.80–1.42) (Supplementary Table 3).
No increased risk of thrombocytopenia events was found for 
the BNT162b2 vaccine (Table 2) during any of the post-vaccination 
time periods. There was no association found for the BNT162b2 
vaccine in the SCCS analysis (Supplementary Table 3).
ITP. For ITP, the aRR in the period 0–27 d after vaccination for 
ChAdOx1 was 5.77 (95% CI, 2.41–13.83). This represents an esti-
mated incidence of 1.13 (0.62–1.63) cases per 100,000 doses. This 
increased risk was first found at 7–13 d after vaccination (aRR = 
4.60, 95% CI, 1.37–15.42) and was most pronounced at 21–27 d 
(aRR = 14.07, 95% CI, 2.46–80.31) (Table 1). The wide CIs reflect the 
small number of incident ITP cases over the study period. The SCCS 
post hoc analysis RR for ChAdOx1 vaccination and ITP (28 d after 
vaccination versus 14 d and 104 d before vaccination) was 1.98 (95% 
CI, 1.29–3.02) (Supplementary Tables 3 and 4). The difference in 
expected versus observed events for ITP during the post-ChAdOx1 
vaccination period for 40–49-year-old individuals was 0.62 events 
(95% CI, 0.01–1.36) per 100,000 doses (Table 3). In the adult popula-
tion studied, the difference in expected versus observed events was 
0.46 events (95% CI, −0.44–1.33) per 100,000 doses.
Patients who had ITP after ChAdOx1 vaccination compared to 
those who were unvaccinated at the time of the event tended to be 
older (median age, 69 years versus 54 years, P = 0.01), to be more 
likely to have at least one clinical risk condition (85% compared to 
40%, P = 0.001) and to have been in hospital at the time of the event 
(52% versus 28%, P = 0.05). The gender distribution was the same 
for ITP after ChAdOx1 vaccination compared to those who were 
unvaccinated. For the 22 patients with post-vaccination ITP and for 
whom platelet counts were available after vaccination, all but two 
had counts below 100,000 per µl. In addition, 48% of patients with 
post-ChAdOx1 ITP had prior prescriptions that could induce ITP, 
compared to 35% of those who were unvaccinated at the time of 
their ITP event. Five or fewer (≤10%) patients with ITP were pre-
scribed ITP therapies by general practitioners in the community 
after vaccination with ChAdOx1.
No positive association was found between the BNT162b2 vac-
cine and ITP (Table 2): aRR at 0–27 d after vaccination was 0.54 
(95% CI, 0.10–3.02). There was also no clear evidence of asso-
ciation found for the BNT162b2 vaccine in the SCCS analysis 
(Supplementary Table 3).
In total, three deaths were reported after ITP. These deaths 
occurred in both vaccinated and unvaccinated individuals all aged 
over 70 and for reasons not associated with ITP.
The number of events per day for ITP since September 2019 is 
available in Extended Data Fig. 2, showing stable rates until January 
2021 when the ChAdOx1 vaccine was introduced in the UK, fol-
lowed by an increase in the number of events per day. Dates of 
vaccination and type of vaccine for individuals with an ITP event 
during the study period are available in Extended Data Fig. 3.
Venous thromboembolic events. We found no association 
between prior ChAdOx1 vaccination and venous thromboem-
bolic events (including CVST) at 0–27 d after vaccination (aRR 
= 1.03, 95% CI, 0.89–1.21) or for the BNT162b2 vaccination 0–27 
d after vaccination (aRR = 0.50, 95% CI, 0.40–0.62). No increase 
in the odds of venous thromboembolic events was found during 
any of the post-vaccination time periods analyzed for ChAdOx1 
(Table 1) or BNT162b2 (Table 2) vaccines. The SCCS analy-
sis for ChAdOx1 and venous thromboembolic events found an 
RR = 0.94 (95% CI, 0.87–1.02) (Supplementary Table 3). No asso-
ciation was found in the SCCS analysis for the BNT162b2 vaccine 
(Supplementary Table 3)
The difference between observed versus expected cases for 
younger age groups after ChAdOx1 vaccination was 10.41 (95% 
CI, 4.64–16.65) per 100,000 doses for 16–39-year-old individuals 
and 9.60 (95% CI, 5.57–13.69) per 100,000 doses for 40–59-year-old 
individuals (Table 4). In the adult population included in the study, 
the difference in expected versus observed events was 4.46 events 
(95% CI, −0.59–9.43) per 100,000 doses.
A subgroup analysis of deep vein thrombosis (DVT) and pul-
monary embolism (PE) found no clear association with ChAdOx1 
vaccination (0–27 d after vaccination: DVT: aRR = 1.21, 95% 
CI, 0.95–1.54; PE: aRR = 0.78, 95% CI, 0.63–0.96) or BNT162b2 
vaccination (0–27 d after vaccination: DVT: aRR = 0.79, 95% CI, 
0.56–1.11; PE: aRR = 0.35, 95% CI, 0.26–0.48).
CVST. When focusing on CVST events, 19 total incident events were 
recorded among all people (vaccinated and unvaccinated). Among 
those vaccinated before the incident event, there were insufficient 
events to adequately power an analysis (n = 6). Post-vaccination inci-
dent events were recorded for both vaccines. Two of those individuals 
with a post-vaccination CVST event died. Platelet count results were 
available for 17 of 19 individuals identified as having CVST. There 
was no evidence of platelet counts <150,000 per µl at any time point 
in any of the 17 individuals with a post-vaccination CVST event.
Arterial thromboembolic events. At 0–27 d after vaccination, 
increased risk between ChAdOx1 vaccination and arterial throm-
boembolic events was found (aRR = 1.22, 95% CI, 1.12–1.34) 
(Table 1). This was first seen at 7–13 d after vaccination (aRR = 
1.25, 95% CI, 1.08–1.44) and also at 14–20 d after vaccination (aRR 
= 1.26, 95% CI, 1.09–1.46). For all ages combined, fewer events were 
observed during the post-vaccination period (3,288) compared 
to 3,328 expected (Table 4). The SCCS analysis RR for ChAdOx1 
and arterial thromboembolic events was 0.97 (95% CI, 0.93–1.02) 
(Supplementary Table 3).
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The observed versus expected cases for younger age groups were 
5.87 (95% CI, 1.83–10.36) per 100,000 doses for 16–39-year-old 
individuals and 31.35 (95% CI, 24.69–38.08) per 100,000 doses for 
40–59-year-old individuals (Table 4).
There was no increased risk of arterial thromboembolic events 
associated with BNT162b2 vaccination at 0–27 d after vaccination 
(aRR = 0.92, 95% CI, 0.81–1.04) or during any of the post-vaccination 
time periods analyzed (Table 2 and Supplementary Table 3).
Hemorrhagic events. At 0–27 d after vaccination, increased risk 
between ChAdOx1 vaccination and hemorrhagic events was found 
(aRR = 1.48, 95% CI, 1.12–1.96) (Table 1). This was first seen at 
Table 1 | Reported thrombocytopenic, venous and arterial thromboembolic and hemorrhagic events for the ChAdOx1 vaccine
Time period after 
vaccination
Number of individualsa Number of eventsb Unadjusted RR  
(95% CI)
Number of risk groups 
adjusted RR (95% CI)
Fully adjusted RR 
(95% CI)c
Thrombocytopenia (excluding ITP)
Unvaccinated 2,343 207 (8.8%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 101 18 (17.8%) 3.54 (1.76–7.10) 2.76 (1.36–5.60) 2.80 (1.39–5.67)
7–13 d 127 8 (6.3%) 0.71 (0.28–1.77) 0.66 (0.27–1.60) 0.69 (0.29–1.67)
14–20 d 95 10 (10.5%) 1.55 (0.66–3.66) 1.12 (0.47–2.65) 1.20 (0.49–2.90)
21–27 d 91 10 (11.0%) 1.86 (0.75–4.58) 1.34 (0.55–3.28) 1.26 (0.51–3.14)
28+ d 407 48 (11.8%) 2.15 (1.18–3.94) 1.55 (0.84–2.88) 1.53 (0.82–2.87)
0–27 d 414 46 (11.1%) 1.82 (1.09–3.03) 1.40 (0.84–2.32) 1.42 (0.86–2.37)
ITP
Unvaccinated 702 58 (8.3%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 35 ≤5 (≤14.3%) 3.95 (1.08–14.52) 3.16 (0.82–12.19) 3.43 (0.88–13.33)
7–13 d 51 7 (13.7%) 4.51 (1.42–14.31) 4.31 (1.32–14.05) 4.60 (1.37–15.42)
14–20 d 39 7 (17.9%) 8.50 (2.53–28.57) 8.62 (2.55–29.07) 7.81 (2.28–26.71)
21–27 d 17 ≤5(≤29.4%) 14.75 (2.67–81.51) 13.85 (2.44–78.62) 14.07 (2.46–80.31)
28+ d 48 ≤5 (≤10.4%) 1.50 (0.27–8.19) 1.29 (0.22–7.54) 1.25 (0.21–7.46)
0–27 d 142 23 (16.2%) 6.01 (2.56–14.07) 5.67 (2.39–13.46) 5.77 (2.41–13.83)
Venous thromboembolic events (including CVST)
Unvaccinated 26,843 2,449 (9.1%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 952 92 (9.7%) 1.13 (0.87–1.46) 0.97 (0.75–1.25) 0.96 (0.74–1.24)
7–13 d 1,074 101 (9.4%) 1.15 (0.89–1.49) 0.95 (0.73–1.22) 0.91 (0.71–1.18)
14–20 d 1,131 130 (11.5%) 1.61 (1.26–2.05) 1.30 (1.02–1.65) 1.23 (0.96–1.57)
21–27 d 953 100 (10.5%) 1.52 (1.16–2.00) 1.17 (0.89–1.54) 1.10 (0.84–1.44)
28+ d 3,616 381 (10.5%) 1.58 (1.30–1.93) 1.20 (0.98–1.47) 1.08 (0.88–1.32)
0–27 d 4,110 423 (10.3%) 1.32 (1.13–1.54) 1.08 (0.92–1.26) 1.03 (0.89–1.21)
Arterial thromboembolic events
Unvaccinated 67,599 5,937 (8.8%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 3,211 303 (9.4%) 1.26 (1.09–1.46) 1.08 (0.94–1.26) 1.08 (0.93–1.25)
7–13 d 3,333 344 (10.3%) 1.54 (1.34–1.78) 1.26 (1.09–1.46) 1.25 (1.08–1.44)
14–20 d 3,352 350 (10.4%) 1.68 (1.45–1.95) 1.29 (1.11–1.50) 1.26 (1.09–1.46)
21–27 d 3,261 351 (10.8%) 1.89 (1.62–2.19) 1.40 (1.20–1.62) 1.37 (1.18–1.60)
28+ d 13,925 1,477 (10.6%) 2.03 (1.81–2.27) 1.37 (1.23–1.54) 1.33 (1.19–1.50)
0–27 d 13,157 1,348 (10.2%) 1.55 (1.41–1.70) 1.24 (1.13–1.36) 1.22 (1.12–1.34)
Hemorrhagic events
Unvaccinated 8,972 785 (8.7%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 337 32 (9.5%) 1.39 (0.87–2.20) 1.22 (0.78–1.93) 1.08 (0.68–1.73)
7–13 d 350 44 (12.6%) 2.22 (1.47–3.37) 1.96 (1.29–2.98) 1.87 (1.23–2.84)
14–20 d 324 38 (11.7%) 2.09 (1.33–3.27) 1.80 (1.15–2.82) 1.67 (1.07–2.62)
21–27 d 314 35 (11.1%) 1.84 (1.16–2.89) 1.53 (0.97–2.42) 1.42 (0.90–2.25)
28+ d 1,316 129 (9.8%) 1.51 (1.06–2.14) 1.18 (0.82–1.68) 1.10 (0.77–1.57)
0–27 d 1,325 149 (11.2%) 1.86 (1.41–2.45) 1.60 (1.21–2.12) 1.48 (1.12–1.96)
aNumber of individuals in the vaccine exposure group. bNumber of events is the number of individuals with an incident consultation in the post-vaccination period. Percent is the number of events divided by 
n and should be equal to 8.34% if there is no association between vaccination and the event representing the 10:1 ratio of controls to cases. cAdjusted for number of clinical risk group, socioeconomic status 
and number of RT–PCR tests an individual had before 8 December 2020. n ≤ 5 denotes minimum allowable reported value.
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7–13 d after vaccination (aRR = 1.87, 95% CI, 1.23–2.84) and 
also at 14–20 d after vaccination (aRR = 1.67, 95% CI, 1.07–2.62). 
For all ages combined, fewer events were observed during the 
post-vaccination period (301 events) compared to 349 expected 
events (Table 4). The SCCS analysis (used to investigate confound-
ing by indication) found no clear evidence of associations between 
ChAdOx1 (RR = 0.95, 95% CI, 0.82–1.11) and hemorrhagic events 
(Supplementary Table 3).
The observed versus expected cases for younger age groups were 
2.22 (95% CI, −0.82–5.81) per 100,000 doses for 16–39-year-old 
individuals and 2.18 (95% CI, -0.11–4.60) per 100,000 doses for 
40–59-year-old individuals (Table 4).
Table 2 | Reported thrombocytopenic, venous and arterial thromboembolic and hemorrhagic events for the BNT162b2 vaccine
Time period after 
vaccination
Number of individualsa Number of eventsb Unadjusted RR  
(95% CI)
Number of risk groups 
adjusted RR (95% CI)
Fully adjusted RR 
(95% CI)c
Thrombocytopenia (excluding ITP)
Unvaccinated 2,343 207 (8.8%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 43 ≤5 (≤11.6%) 1.05 (0.29–3.78) 0.89 (0.25–3.23) 0.84 (0.23–3.08)
7–13 d 51 7 (14.6%) 2.10 (0.71–6.18) 1.71 (0.56–5.27) 1.80 (0.59–5.50)
14–20 d 34 0 (0.0%) 0.00 (0.00–Inf) 0.00 (0.00–Inf) 0.00 (0.00–Inf)
21–27 d 45 ≤5 (≤11.1%) 0.32 (0.05–1.94) 0.35 (0.05–2.30) 0.35 (0.05–2.28)
28+ d 250 21 (8.4%) 1.06 (0.56–2.03) 0.91 (0.47–1.75) 0.80 (0.41–1.54)
0–27 d 173 13 (7.5%) 0.79 (0.37–1.67) 0.68 (0.32–1.45) 0.67 (0.32–1.43)
ITP
Unvaccinated 702 58 (8.3%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d ≤5 0 (0%) 0.00 (0.00–Inf) 0.00 (0.00–Inf) 0.00 (0.00–Inf)
7–13 d 15 ≤5 (≤33.3%) 0.53 (0.04–8.05) 0.54 (0.03–8.41) 0.61 (0.04–9.28)
14–20 d 18 0 (0%) 0.00 (0.00–Inf) 0.00 (0.00–Inf) 0.00 (0.00–Inf)
21–27 d 11 ≤5 (≤45.5%) 1.31 (0.16–10.45) 1.41 (0.18–11.31) 1.46 (0.18–12.01)
28+ d 49 5 (10.2%) 1.52 (0.47–4.88) 1.49 (0.45–4.91) 1.68 (0.48–5.87)
0–27 d 45 ≤5 (≤5.8%) 0.44 (0.08–2.36) 0.50 (0.09–2.76) 0.54 (0.10–3.02)
Venous thromboembolic events (including CVST)
Unvaccinated 26,843 2,449 (9.1%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 460 26 (5.7%) 0.46 (0.29–0.72) 0.43 (0.27–0.67) 0.40 (0.26–0.63)
7–13 d 589 38 (6.5%) 0.54 (0.36–0.81) 0.49 (0.33–0.74) 0.45 (0.30–0.67)
14–20 d 547 37 (6.8%) 0.59 (0.39–0.89) 0.52 (0.34–0.79) 0.48 (0.32–0.73)
21–27 d 448 36 (8.0%) 0.80 (0.52–1.22) 0.72 (0.47–1.10) 0.64 (0.42–0.97)
28+ d 2,299 203 (8.8%) 1.02 (0.83–1.25) 0.88 (0.72–1.08) 0.73 (0.60–0.90)
0–27 d 2,044 137 (6.7%) 0.58 (0.47–0.73) 0.53 (0.42–0.66) 0.48 (0.39–0.61)
Arterial thromboembolic events
Unvaccinated 26,843 2,449 (9.1%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 460 26 (5.7%) 0.46 (0.29–0.72) 0.43 (0.27–0.67) 0.40 (0.26–0.63)
7–13 d 589 38 (6,5%) 0.54 (0.36–0.81) 0.49 (0.33–0.74) 0.45 (0.30–0.67)
14–20 d 547 37 (6.8%) 0.59 (0.39–0.89) 0.52 (0.34–0.79) 0.48 (0.32–0.73)
21–27 d 448 36 (8.0%) 0.80 (0.52–1.22) 0.72 (0.47–1.10) 0.64 (0.42–0.97)
28+ d 2,299 203 (8.8%) 1.02 (0.83–1.25) 0.88 (0.72–1.08) 0.73 (0.60–0.90)
0–27 d 2,044 137 (6.7%) 0.58 (0.47–0.73) 0.53 (0.42–0.66) 0.48 (0.39–0.61)
Hemorrhagic events
Unvaccinated 8,972 785 (8.7%) 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
0–6 d 132 16 (12.1%) 1.69 (0.92–3.09) 1.40 (0.76–2.58) 1.10 (0.59–2.06)
7–13 d 157 13 (8.3%) 1.08 (0.56–2.09) 0.93 (0.47–1.81) 0.76 (0.39–1.50)
14–20 d 189 21 (11.1%) 1.62 (0.91–2.88) 1.40 (0.79–2.50) 1.27 (0.71–2.27)
21–27 d 169 11 (6.5%) 0.79 (0.39–1.57) 0.70 (0.35–1.41) 0.60 (0.30–1.22)
28+ d 762 76 (10%) 1.44 (1.04–2.00) 1.26 (0.90–1.76) 1.07 (0.76–1.51)
0–27 d 647 61 (9.4%) 1.25 (0.89–1.77) 1.08 (0.77–1.53) 0.92 (0.64–1.30)
Inf, infinity. aNumber of individuals in the vaccine exposure group. bNumber of events is the number of individuals with an incident consultation in the post-vaccination period. Percent is the number of 
events divided by n and should be equal to 9.1% if there is no association between vaccination and the event representing the 10:1 ratio of controls to cases. cAdjusted for number of clinical risk group, 
socioeconomic status and number of RT–PCR tests an individual had before 8 December 2020. n ≤ 5 denotes minimum allowable reported value.
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There was no increased risk of hemorrhagic events associated 
with BNT162b2 vaccination at 0–27 d after vaccination (aRR = 
0.92, 95% CI, 0.64–1.30) or during any of the post-vaccination time 
periods analyzed (Table 2). There was also no clear evidence of asso-
ciation found for the BNT162b2 vaccine (Supplementary Table 3).
Multiple outcomes and predictors. Overlap in our outcomes with 
individuals presenting with multiple events of interest was rare. 
Among those vaccinated with ChAdOx1, there were six occur-
rences of ITP with hemorrhagic, venous thromboembolic or throm-
bocytopenia events, with the most common combination being ITP 
and thrombocytopenia.
We found increased risk for post-vaccination ITP and arterial 
thromboembolic and hemorrhagic events combined associated 
with increasing age (especially over 60), male sex, having certain 
comorbidities (such as heart failure, coronary heart disease, periph-
eral vascular disease, severe mental illness, sickle cell disease, prior 
stroke, type 1 and 2 diabetes and chronic kidney disease (stage 5)), 
very high blood pressure and smoking (Supplementary Table 5).
Sensitivity analyses. Restricting the end date of analysis to 21 
February 2021 for ITP and hemorrhagic events resulted in fewer 
ChAdOx1-associated events and similar RRs with wider CIs (ITP: 
aRR = 8.80, 95% CI, 0.70–108.00; arterial thromboembolic event: 
aRR = 1.11, 95% CI, 0.96–1.28; hemorrhagic event: aRR = 1.16, 
95% CI, 0.71–1.90). Restricting to those who never tested positive 
previously for severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) revealed similar RRs (ITP: 6.06, 95% CI, 2.28–16.12; 
arterial thromboembolic: 1.28, 95% CI, 1.16–1.41; hemorrhagic 
event: 1.57; 95% CI, 1.17–2.10). Additional adjustment for specific 
health conditions did not substantively change the estimated asso-
ciations for ChAdOx1 and ITP (Supplementary Table 2).
Discussion
This Scottish national population-based analysis among 2.53 mil-
lion people who received their first doses of SARS-CoV-2 vac-
cines reveals a potential association between receiving a first-dose 
ChAdOx1 vaccination and occurrence of ITP, with an incidence of 
1.13 cases per 100,000 vaccinations. For ChAdOx1 vaccination, there 
was suggestive evidence of an association with arterial thromboem-
bolic and hemorrhagic events. For these outcomes, an attenuation 
of effect was found in the SCCS analysis, which might indicate the 
presence of residual confounding or confounding by indication. For 
any venous thromboembolic event, there were more observed than 
expected events for younger age groups (16–59 years old) associ-
ated with ChAdOx1, but this was not seen in our primary incident 
case–control analysis. Because of our limited ability to match in the 
observed versus expected analysis, this finding should be treated 
with considerable caution. There were 19 incident CVST events 
seen in our study population: 6 of these occurred after vaccination, 
with these events being seen after both ChAdOx1 and BNT162b2 
vaccines. Two individuals with post-vaccination CVST events died. 
For CVST (and other rare conditions), there were insufficient num-
bers to draw any reliable conclusions other than, if there is any asso-
ciation, it is likely to represent an extremely rare outcome. For the 
BNT162b2 vaccine, our analysis found no evidence of increased 
adverse events for the thrombocytopenic, venous thromboembolic 
or hemorrhagic outcomes of interest.
To our knowledge, this is the one of the first real-world con-
temporaneous studies identifying all vaccinated individuals within 
a national population and assessing COVID-19 vaccine-related 
thrombocytopenic, venous or arterial thromboembolic and hemor-
rhagic adverse events. One published study of people aged 18–65 
years who received the ChAdOx1 vaccine in Denmark and Norway 
observed increased rates of venous thromboembolic events, including 
cerebral venous thrombosis (standardized morbidity ratio of 1.97 
and 95% CI, 1.50–2.54) and intracerebral hemorrhage (standard-
ized morbidity ratio of 2.33 and 95% CI, 1.01–4.59)23. In that study, 
Pottegård et al. found a standardized morbidity ratio for any throm-
bocytopenia/coagulation disorders of 1.52 (0.97–2.25) and for any 
bleeding of 1.23 (0.97–1.55).
Our study has several strengths, including our ability to rapidly 
access and analyze data on vaccination status and medical and death 
records from linked national databases24–26. This study is, therefore, 
less susceptible to recall or misclassification bias than studies of 
samples of the population. A large population aided study power to 
facilitate the analysis of rare events such as ITP. We think that our 
findings have generalizability across countries using these vaccines 
as part of national vaccination programs that have prioritized vac-
cination of high-risk populations.
Our study has several limitations. As few individuals had 
received two vaccine doses at the time of analysis, this (second-dose) 




















16–39 181,635 ≤5d ≤5d 1.17 (−1.83–5.13) ≤5d ≤5d 2.62 (−0.38–6.62)
40–59 740,800 22 14.3 7.71 (−2.71–18.63) 6 1.4 4.58 (0.10–10.05)
60–79 606,854 49 40.6 8.41 (−10.08–27.10) 14 7.1 6.85 (−2.23–15.96)
80+ 178,673 32 26.6 5.40 (−12.89–23.00) 5 11.3 −6.26 (−16.76–3.25)
BNT162b2
16–39 144,393 7 3.8 3.23 (−1.85–9.30) ≤5d ≤5d 1.20 (−1.13–4.47)
40–59 230,802 6 13.0 −7.00 (−13.59–0.07) ≤5d ≤5d (−0.33(−2.66–2.23)
60–79 409,429 27 34.2 −7.24 (−21.63–7.54) ≤5d ≤5d −2.05 (−8.24–3.81)
80+ 36,428 ≤5d ≤5d −3.38 (−8.02–1.53) 0 2.7 −2.70 (−4.96–0.90)
aThe observed events were incident cases after vaccination counted for the observed duration of the post-vaccination period. bThe expected events are the number of events per day in the pre-vaccination 
period divided by the population and multiplied by the days at risk in the post-vaccination period for all vaccinated and then summed. cThe difference between expected (the number of events per day in 
the pre-vaccination period divided by the population and multiplied by the days at risk in the post-vaccination period for all vaccinated and then summed) and observed events during the post-vaccination 
period, with CIs obtained from a parametric bootstrap, was based on the Poisson distribution using 10,000 samples. There was limited opportunity for matching in this analysis, and the findings, therefore, 
need to be interpreted with caution. dn ≤ 5 denotes minimum allowable reported value.
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subgroup was not investigated separately. A further analysis on 
second doses will be conducted in due course. Furthermore, our 
study included few young vaccinated people (<40 years), especially 
for the ChAdOx1 vaccine, because the vaccination program has 
been predominantly targeted by age and underlying comorbidities 
so far. Although electronic general practice records of hospitaliza-
tion and deaths were accessible, and linked with hospitalization and 
mortality records, lags in final coded hospital discharge data and 
postmortem changes to death certification might have resulted in 
over-riding of initial recorded causes of hospitalizations and deaths 
in some instances. However, our sensitivity analysis restricting to 
an earlier date of follow-up is less subject to such potential biases 
and found similar results. Additionally, ITP is a diagnosis of exclu-
sion. Given that we based this analysis on clinician-recorded data, 
we had to assume that clinicians had appropriately investigated 
patients for their thrombocytopenia before recording this diagno-
sis. Discussions with Scottish hematologists indicated that this was 
a reasonable assumption, as the diagnosis of ITP is made only by 
specialists in a Scottish context. However, there can be uncertainty 
about the diagnosis of ITP, and published experience indicates that 
the diagnosis of ITP is often changed when patients are followed 
by skilled hematologists27,28. There is also the possibility that some 
of these cases of ITP could have represented reactivation of disease 
that had been in remission for more than 1 year. We did, however, 
carry out a post hoc analysis of all post-vaccination ITP events 
for those with prior available platelet count (tested in the primary 
care setting) and relevant prescriptions that could cause thrombo-
cytopenia. We also carried out an analysis of ITP-directed therapy 
after vaccination (including oral corticosteroids). We were unable 
to access blood smear information as this is not routinely captured 
in the record systems that we had access to. Furthermore, 48% of 
patients with post-ChAdOx1 ITP events had prior prescriptions 
that could induce ITP, compared to 35% of those who were unvac-
cinated at the time of their ITP event. ITP-directed therapy pre-
scribed by general practitioners in the community to patients with 
post-vaccination ITP was uncommon (≤10%). The overwhelming 
majority of ITP-directed therapy (for example, pulsed dexamatha-
sone, prednisolone with or without intravenous immunoglobulin, 
rituximab and immunosuppressants) is, however, is likely to have 
been initiated in the hospital setting by hematologists, but these 
data were not accessible to us, as hospital prescribing in Scotland 
remains predominantly paper based29. These patients with commu-
nity prescribing of oral corticosteroids are likely to have had persis-
tent ITP that was managed in primary care.
Although we used a nested case–control study design matched 
by age, sex and geography, and adjusted for several confounders, 
unmeasured confounders could still have influenced our estimates 
(Supplementary Table 2). To mitigate this risk, where associations 
between ChAdOx1 and any adverse event were seen (that is, ITP 
and arterial thromboembolic and hemorrhagic events), we con-
ducted a confirmatory post hoc SCCS analysis. SCCS designs can 
account for time-invariant confounding but are less suitable where 
recurrent events are not independent. Although the pattern of find-
ings was largely similar across different analytical approaches, it is 
worth noting that the magnitude of associations did differ. Estimates 
tended to be greater in the case–control analysis, which could arise 
from potential residual confounding by indication that would most 
likely result in an overestimate of the real effect sizes. By contrast, the 
SCCS analysis tended to estimate smaller effect sizes, but the poten-
tial correlation of outcomes within an individual over time could 
bias estimates toward the null. The two approaches, therefore, pro-
vide reasonable bounds for the true effect, with our primary results 
potentially overestimating the risk of vaccine-associated harm and, 
therefore, being the most conservative for decision-making. Owing 
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16–39 181,635 30 11.1 18.90 
(8.42–30.25)
15 4.3 10.67 (3.33–18.81) 9 5.0 4.04 
(−1.57–10.47)
40–59 740,800 178 106.9 71.11 
(41.66–100.51)
516 283.8 232.23 
(182.63–282.63)
58 41.9 16.13 
(−0.85–34.07)
60–79 606,854 439 423.4 15.60 
(−44.53–74.57)
1,600 1,521.0 78.96 
(−32.80–188.70)
131 149.9 −18.85 
(−52.50–14.35)
80+ 178,673 246 275.3 −29.28 
(−83.56–25.40)
1,157 1,519.0 −362.03 
(−488.57–239.94)
103 151.9 −48.95 
(−87.64–10.46)
BNT162b2
16–39 144,393 24 22.9 1.09 
(−9.34–12.21)
5 8.9 −3.90 
(−8.95–1.79)
10 10.2 −0.24 
(−6.86–7.11)
40–59 230,802 80 97.3 −17.29 
(−38.85–4.78)
217 258.0 −41.00 
(−76.37–4.39)
37 38.1 −1.11 
(−15.32–13.30)
60–79 409,429 259 357.2 −98.22 
(−144.82–51.85)
1,156 1,283.4 −127.38 
(−222.72–35.17)
88 126.4 −38.41 
(−65.85–11.24)
80+ 36,428 58 66.0 −8.00 
(−26.38–11.01)
225 364.0 −138.96 
(−177.19–99.42)
29 36.4 −7.43 
(−20.35–6.31)
aThe observed events were incident cases after vaccination counted for the observed duration of the post-vaccination period. bThe expected events are the number of events per day in the pre-vaccination 
period divided by the population and multiplied by the days at risk in the post-vaccination period for all vaccinated and then summed. cThe difference between expected (the number of events per day in 
the pre-vaccination period divided by the population and multiplied by the days at risk in the post-vaccination period for all vaccinated and then summed) and observed events during the post-vaccination 
period, with CIs obtained from a parametric bootstrap, was based on the Poisson distribution using 10,000 samples. There was limited opportunity for matching in this analysis, and the findings, therefore, 
need to be interpreted with caution.
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to the small number of adverse events, to identify predictors among 
vaccinated individuals we combined the outcomes of interest: ITP 
and arterial thromboembolic and hemorrhagic events. This as an 
area for future work, for instance through a meta-analyses of vac-
cine safety studies. Finally, the EAVE II platform is a national pub-
lic health surveillance platform that was established at the request 
of the Scottish Government to help inform the public health 
response to the pandemic. It brought together a range of national 
whole-population healthcare datasets for the first time into Public 
Health Scotland. Ethical permission for this study was granted, and 
the Public Benefit and Privacy Panel Committee of Public Health 
Scotland approved the linkage and analysis of the de-identified 
datasets. As the policy aim was for national coverage, it was not fea-
sible to obtain individual patient consent. This, therefore, restricted 
our ability to interrogate and report on certain individual record 
data in detail. For CVST, for instance, there were very few events, 
and, in keeping with our permissions, we suppressed the actual 
number of events found to minimize the risk of inadvertent dis-
closure of identity30. Also, centralized adjudication of our outcomes 
through case record review by an independent group of experts was 
not possible because access to data was limited to a small number of 
approved researchers.
The Centers for Disease Control and Prevention estimated that 
60,000–100,000 Americans die annually due to venous throm-
boembolism (United States of America: 2.8 million deaths annu-
ally)31. Venous thromboembolic events are common in patients 
with COVID-19. Approximately 10% of patients with COVID-
19 in hospitals (non-intensive care unit (ICU)) are diagnosed 
with venous thromboembolism and 28% of those in ICU11,32,33,34. 
The vaccine-induced adverse events after administration of the 
adenovirus-based SARS-CoV-2 vaccines (including the ChAdOx1 
vaccine) have been described as vaccine-induced immune throm-
botic thrombocytopenia (VITT) syndrome or thrombosis with 
thrombocytopenia syndrome resulting in a venous or arterial 
thrombosis, including CVST and thrombocytopenia35. The syn-
drome has been characterized as being similar to heparin-induced 
thrombocytopenia, a pro-thrombotic adverse drug reaction caused 
by the transient production of platelet-activating antibodies of IgG 
class that recognize multi-molecular complexes of (cationic) platelet 
factor 4 bound to (polyanionic) heparin36. We were insufficiently 
powered to provide estimates of the rarer VITT CVST and splanch-
nic vein thrombosis. This is an area for further work likely best pur-
sued through larger datasets and meta-analyses.
ITP has also emerged as an important complication of COVID-19, 
with early epidemiological evidence suggesting a rate of 0.34% among 
hospitalized patients. There have also been reports of post-vaccination 
ITP in patients who received mRNA vaccines (including BNT162b2), 
and it has been postulated that some individuals might have had 
mild ‘compensated’ thrombocytopenia of diverse causes, and severe 
thrombocytopenia might have been induced by enhancement of 
macrophage‐mediated clearance or impaired platelet production as 
part of a systemic inflammatory response to vaccination21. ITP, how-
ever, as an adverse event after vaccine administration, is very rare. 
Our study suggests that there might be an increase in the risk of this 
very rare outcome for ChAdOx1 that is similar to other vaccines, 
including hepatitis B; measles, mumps and rubella; and influenza37,38. 
This very small risk is important but needs to be seen within the con-
text of the very clear benefits of the ChAdOx1 vaccine.
As a result of findings from UK pharmacovigilance and surveil-
lance data (including from EAVE II investigators), advice was issued 
in April 2021 regarding age group limits for the ChAdOx1 vaccine 
for individuals younger than 30 years of age18 and then, in May 
2021, for individuals younger than 40 years of age19. Replication 
of our study in other countries is needed to confirm our results. 
We plan to update our analysis as the vaccine program is extended 
to younger, healthier individuals and as new vaccines become 
available. We also plan to extend our pharmacovigilance efforts to 
cover the second doses of these and other vaccines.
In conclusion, we did not identify any overall increased risk in 
the adverse events of interest in individuals receiving BNT162b2. 
First dose of ChAdOx1 was found to be associated with small 
increased risks of ITP, with suggestive evidence of an increased risk 
of arterial thromboembolic and hemorrhagic events. Given these 
small increased risks for ChAdOx1, alternative vaccines for individ-
uals at low COVID-19 risk might be warranted when supply allows.
Online content
Any methods, additional references, Nature Research report-
ing summaries, source data, extended data, supplementary infor-
mation, acknowledgements, peer review information; details of 
author contributions and competing interests; and statements of 
data and code availability are available at https://doi.org/10.1038/
s41591-021-01408-4.
Received: 4 May 2021; Accepted: 26 May 2021;  
Published: xx xx xxxx
References
 1. Joint Committee on Vaccination and Immunisation. Priority groups for 




 2. Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and 
Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital 
admissions, and mortality in older adults in England: test negative 
case-control study. Br. Med. J. 373, n1088 (2021).
 3. Vasileiou, E et al. Interim findings from first dose mass COVID-19 
vaccination roll-out and COVID-19 hospitalisations in Scotland:  
national prospective cohort study of 5.4 million people. Lancet 397, 
1646–1657 (2021).
 4. Simpson, C. R. et al. Evaluating the effectiveness, impact and safety of live 
attenuated and seasonal inactivated influenza vaccination: protocol for the 
Seasonal Influenza Vaccination Effectiveness II (SIVE II) study. BMJ Open 7, 
e014200 (2017).
 5. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 
vaccine. N. Engl. J. Med. 384, 403–416 (2021).








 8. COVID-19 vaccine Moderna product information sheet. https://assets.
publishing.service.gov.uk/government/uploads/system/uploads/attachment_
data/file/955847/Information_for_HCP_Moderna_26012021.pdf (2020).
 9. Medicines & Healthcare Products Regulatory Agency. Coronavirus vaccine 
- weekly summary of Yellow Card reporting. https://www.gov.uk/government/ 
publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus- 
vaccine-summary-of-yellow-card-reporting#analysis-of-data (2021).
 10. Wise, J. Covid-19: European countries suspend use of Oxford–AstraZeneca 
vaccine after reports of blood clots. Br. Med. J. 372, n699 (2021).
 11. Greinacher, A. et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 
vaccination. N. Engl. J. Med. https://www.nejm.org/doi/10.1056/
NEJMoa2104840 (2021).
 12. Schultz, N. H. et al. Thrombosis and thrombocytopenia after ChAdOx1 
nCoV-19 vaccination. N. Engl. J. Med. https://www.nejm.org/doi/10.1056/
NEJMoa2104882 (2021).
 13. Scully, M. et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 
nCoV-19 vaccination. N. Engl. J. Med. https://doi.org/10.1056/
NEJMoa2105385 (2021).
 14. European Medicines Agency. COVID-19 Vaccine AstraZeneca: benefits still 
outweigh the risks despite possible link to rare blood clots with low blood 
platelets. https://www.ema.europa. eu/en/news/covid-19- vaccine-astrazeneca- 
benefits-still- outweigh-risks- despite-possible- link-rare-blood- clots (2021).
 15. European Medicines Agency. AstraZeneca’s COVID-19 vaccine: EMA finds 
possible link to very rare cases of unusual blood clots with low blood platelets. 
https://www.ema.europa. eu/en/news/astrazenecas-covid-19-vaccine-ema-finds- 
possible-link-very-rare-cases-unusual-blood-clots-low-blood (2021).
NATURE MEDICINE | www.nature.com/naturemedicine
Articles Nature MediciNe
 16. European Medicines Agency Pharmacovigilance Risk Assessment Committee 
(PRAC). Signal assessment report on embolic and thrombotic events (SMQ) 
with COVID-19 Vaccine (ChAdOx1-S [recombinant]) – Vaxzevria 




 17. Medicines & Healthcare Products Regulatory Agency. Coronavirus vaccine 
- weekly summary of Yellow Card reporting. https://www.gov.uk/government/
publications/coronavirus-covid-19-vaccine-adverse-reactions/
coronavirus-vaccine-summary-of-yellow-card-reporting (2021).
 18. Joint Committee on Vaccination and Immunisation. JCVI statement on use of 




 19. Joint Committee on Vaccination and Immunisation. JCVI advises on 
COVID-19 vaccine for people aged under 40. https://www.gov.uk/government/
news/jcvi-advises-on-covid-19-vaccine-for-people-aged-under-40 (2021).
 20. Toom, S., Wolf, B., Avula, A., Peeke, S. & Becker, K. Familial 
thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 
vaccine. Am. J. Hematol. 96, E134–E135 (2021).
 21. Lee, E.-J. et al. Thrombocytopenia following Pfizer and Moderna 
SARS-CoV-2 vaccination. Am. J. Hematol. 96, 534–537 (2021).
 22. Tarawneh, O. & Tarawneh, H. Immune thrombocytopenia in a 22-year-old 
post Covid-19 vaccine. Am. J. Hematol. 96, E133–E134 (2021).
 23. Pottegård, A. et al. Arterial events, venous thromboembolism, 
thrombocytopenia, and bleeding after vaccination with Oxford–AstraZeneca 
ChAdOx1-S in Denmark and Norway: population based cohort study.  
Br. Med. J. 373, n1114 (2021).
 24. Simpson, C. R. et al. Early Pandemic Evaluation and Enhanced Surveillance 
of COVID-19 (EAVE II): protocol for an observational study using linked 
Scottish national data. BMJ Open 10, e039097 (2020).
 25. Simpson, C. R. et al. The UK’s pandemic influenza research portfolio: a 
model for future research on emerging infections. Lancet Infect. Dis. 19, 
e295–e300 (2019).
 26. Simpson, C. R. et al. The UK hibernated pandemic influenza research 
portfolio: triggered for COVID-19. Lancet Infect. Dis. 20, 767–769 (2020).
 27. Arnold, D. M. et al. Misdiagnosis of primary immune thrombocytopenia and 
frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv. 1, 
2414–2420 (2017).
 28. Schifferli, A. et al. Misdiagnosed thrombocytopenia in children and 
adolescents: analysis of the Pediatric and Adult Registry on Chronic ITP. 
Blood Adv. 5, 1617–1626 (2021).
 29. Cresswell, K., Slee, A. & Sheikh, A. Five key recommendations for the 
implementation of Hospital Electronic Prescribing and Medicines 
Administration systems in Scotland. J. Innov. Health Inform. 23,  
904 (2017).
 30. eDRIS Team. Researcher guide: requesting outputs from Safe Haven and 
disclosure control. https://www.isdscotland.org/products-and-services/edris/_
docs/Researcher-guide-to-disclosure-control-V1-2.pdf (2018).
 31. Centers for Disease Control and Prevention. Data and statistics on venous 
thromboembolism. https://www.cdc.gov/ncbddd/dvt/data.html (2020).
 32. Boonyawat, K. et al. Incidence of thromboembolism in patients with 
COVID-19: a systematic review and meta-analysis. Thromb. J. 18, 34 (2020).
 33. Bhattacharjee, S. & Banerjee, M. Immune thrombocytopenia secondary to 
COVID-19: a systematic review. SN Compr. Clin. Med. https://doi.
org/10.1007/s42399-020-00521-8 (2020).
 34. Kewan, T. et al. Outcomes and management of immune thrombocytopenia 
secondary to COVID-19: Cleveland Clinic experience. Transfusion https://doi.
org/10.1111/trf.16368 (2021).
 35. American Society of Hematology. Thrombosis with thrombocytopenia 
syndrome (also termed vaccine-induced thrombotic thrombocytopenia). 
https://www.hematology.org/covid-19/vaccine-induced-immune-thrombotic- 
thrombocytopenia (2021).
 36. Greinacher, A., Selleng, K. & Warkentin, T. E. Autoimmune heparin-induced 
thrombocytopenia. J. Thromb. Haemost. 15, 2099–2114 (2017).
 37. Perricone, C. et al. Immune thrombocytopenic purpura (ITP) associated with 
vaccinations: a review of reported cases. Immunol. Res. 60, 226–235 (2014).
 38. Cecinati, V., Principi, N., Brescia, L., Giordano, P. & Esposito, S. Vaccine 
administration and the development of immune thrombocytopenic purpura 
in children. Hum. Vaccin. Immunother. 9, 1158–1162 (2013).
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in 
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons 
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, provide a link to 
the Creative Commons license, and indicate if changes were made. The images or other 
third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons license and your intended use is not permitted by statu-
tory regulation or exceeds the permitted use, you will need to obtain permission directly 
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
NATURE MEDICINE | www.nature.com/naturemedicine
ArticlesNature MediciNe
Methods
Ethics and permissions. Ethical permission for this study was granted by the 
South East Scotland Research Ethics Committee 02 (12/SS/0201). The Public 
Benefit and Privacy Panel Committee of Public Health Scotland approved the 
linkage and analysis of the de-identified datasets for this project (1920–0279).
Study setting and population. The National Health Service in Scotland (NHS 
Scotland) provides comprehensive health services that are free at the point of 
care for all residents. Our base population for this study was 5.4 million residents 
(~99% of the population) registered with a general medical practice in Scotland.
Study design. Following a pre-specified analysis plan, we started with a matched 
case–control study nested within the EAVE II prospective cohort. A case was 
defined as anyone with a recorded incident event of thrombocytopenia, venous 
thromboembolism, arterial thromboembolism or hemorrhage after the start of 
the COVID-19 vaccination program in Scotland. The general practice clinical 
data contained records of the specified events from 1 September 2019 to 14 
April 2021. An incident case was defined as the first event in the period from 
when vaccination started on 8 December 2020 with no prior thrombocytopenic, 
venous thromboembolic or hemorrhagic clinical events since 1 September 
2019. We matched cases who had experienced the outcomes of interest during 
the period from 8 December 2020 to 14 April 2021 based on recording of 
demographic and pre-existing comorbidities (Supplementary Table 2) to controls 
who had not yet experienced the outcome in an incident-matched nested 
case–control design. Incident cases were matched to controls based on age (in 
exact years up to 80 years old and then 2-year age groups up to 90 years old and 
5-year age bands above that to allow for sparse data), sex and area of residence 
using Intermediate Zone classification. There are 1,271 such zones in Scotland 
(comprising between 2,500 and 6,000 households, with an average population 
of 4,200), which are geographically aligned with general practices. Ten controls 
were selected per case. Diagnosis dates of the cases were taken as the index dates 
for the controls.
We investigated confounding by indication and carried out a post hoc SCSS 
analysis to estimate the risk of COVID-19 vaccination and ITP events using 
conditional logistic regression with an offset for the length of the risk period39.
Data sources. Almost all residents in Scotland are registered with a general practice 
and have a unique Community Health Index (CHI) number used by NHS Scotland. 
We used the CHI number to deterministically link all datasets with vaccination 
records in Public Health Scotland (Extended Data Fig. 4). Vaccination information 
was extracted from the general practice records and the Turas Vaccination 
Management Tool system; together, these captured all vaccination records, 
including those vaccinated in general practices, community vaccination hubs and 
other settings, such as care homes and hospitals in Scotland40. Further details on the 
data sources used in this study are available in a published project protocol24.
Exposure definition. We studied the first doses of the BNT162b2 (ref. 41) and 
ChAdOx1 (ref. 42) vaccines. An individual was defined as exposed to each vaccine 
if they received their first dose of vaccine between 8 December 2020 and 14 April 
2021. Given the limited number of people who had received their second vaccine 
dose by this time, we have reported only on first-dose-associated events.
Outcomes. The outcomes analyzed in this study were one or more  
(1) thrombocytopenic, (2) arterial or venous thromboembolic or (3) hemorrhagic 
(excluding traumatic, gastrointestinal and genitourinary bleeding) events. We 
undertook additional a priori subgroup analyses focused on ITP and CVST and 
post hoc subgroup analyses for DVT and PE43. Read codes (version 2) were used to 
determine adverse incident events recorded in the primary care electronic health 
record (Supplementary Table 6), which were then followed up in the linked RAPID 
dataset and National Records Scotland for hospitalization and mortality outcomes, 
respectively (Extended Data Fig. 4).
Covariates. Data on the number of comorbidities recorded in the general practice 
record were derived from the QCovid risk groups on 1 December 2020 (ref. 22).  
Socioeconomic status was measured by quintiles of the Scottish Index of Multiple 
Deprivation18. The number of pre-vaccination program RT–PCR tests was 
extracted from the records as a marker of being in a population at high risk of 
exposure (for example, health and social care workers in whom regular testing  
was recommended).
Statistical analysis. Conditional logistic regression analysis was used with case 
and control matching groups as the strata. The unadjusted model included no 
covariates other than the strata and the exposure. Separately, a simple adjustment 
was made for the number of clinical risk groups per patient44. Then, a full 
adjustment included socioeconomic status24 and number of RT–PCR tests an 
individual had before 8 December 2020, because we considered a priori these 
variables to affect vaccination receipt (all three) and risk of outcomes (risk 
groups and deprivation). Odds ratios for being a case among vaccinated versus 
unvaccinated individuals were estimated from the logistic regression, which, given 
the incidence–density sampling design, are mathematically equivalent to RRs. 
Unadjusted and adjusted RRs, along with 95% CIs, were calculated. Additionally, 
we investigated the individual QCovid risk groups as potential confounding 
variables (through statistical adjustment) or effect-modifying variables (through 
interaction)44. We also identified predictors (QCovid risk groups and age) for our 
combined outcomes events of interest, namely ITP and hemorrhage and arterial 
thromboembolic events.
We carried out an analysis of observed incident cases in the post-vaccination 
period compared to those expected from a pre-vaccination period. The 
pre-vaccination period used was the 28-d period after 1 October 2020. For the 
event to be incident, there were no thrombocytopenic, venous thromboembolic 
or hemorrhagic events in the same individual in the period from 1 September 
2019. In the post-vaccination period, clinical events were linked to the vaccination 
records, and incident cases after vaccination were counted for the observed 
duration of the post-vaccination period. The expected events were the number 
of events per day in the pre-vaccination period divided by the population and 
multiplied by the days at risk in the post-vaccination period for all vaccinated 
and then summed. The difference between expected and observed events during 
the post-vaccination period was used to calculate expected additional cases per 
100,000 vaccine doses. CIs were obtained from a parametric bootstrap based on the 
Poisson distribution using 10,000 samples.
Analyses were carried out by one statistician (C.R.) and independently checked 
by additional statisticians (E.M., U.A. and R.M.). All analyses were carried out with 
R software version 3.6.1 (ref. 45).
Post-hoc analyses. The nested case–control method was used in our primary 
analysis, as opposed to an SCCS method, because recurrent adverse events of 
interest were considered unlikely to be independent. Nonetheless, we investigated 
confounding by indication and carried out a post hoc SCSS analysis to estimate the 
risk of COVID-19 vaccination and the adverse events of interest using conditional 
logistic regression with an offset for the length of the risk period39. This analysis 
compared risk for the same individuals in the time periods before and after 
vaccination. We considered the time period from the date of first vaccination 
dose to 28 d after as the risk (exposed) period. The control (pre-risk) period was 
the 90-d period before 14 d before vaccination (that is, 15–104 d before vaccine 
receipt), allowing for a 14-d clearance period. The main comparisons were the rate 
of adverse events between (1) the risk period and the pre-risk period and (2) the 
clearance period and the pre-risk period (Fig. 1).
As an additional post hoc analysis to understand whether cases of ITP could 
have represented reactivation of disease and whether relevant prescriptions that 
could cause thrombocytopenia were prescribed and ITP-directed therapy after 
vaccination was administered, platelet counts for individuals with the outcome 
were extracted from the general practice electronic health record (Extended Data 
Fig. 4), and prescriptions were extracted that could cause thrombocytopenia 
(including amiodarone cephalosporins, ciprofloxacin, ethambutol, furosemide, 
glycoprotein IIb/IIIa inhibitors (tirofiban, abciximab and eptifibatide), haloperidol, 
heparin, ibuprofen, irinotecan, linezolid, mirtazapine, naproxen, oxaliplatin, 
paracetamol, penicillins, phenytoin, quinidine, quinine, rifampicin, salmeterol, 
sodium valproate, sulphonamides, tacrolimus thiazides, trimethoprim and 
vancomycin). The following ITP-related prescriptions were extracted: azathioprine, 
ciclosporin, cyclophosphamide, danazol, dapsone, intravenous immunoglobulin, 
mycophenolate, oral corticosteroids, rituximab, vinca alkaloids, eltrombopag and 
romiplostim therapy.
Sensitivity analyses. To reduce the potential for ascertainment bias, we carried  
out a sensitivity analysis with a censoring date before the first media reports  
of possible thrombotic events associated with ChAdOx1 (that is, 21 February 
2021)46. An analysis to explore any influence on testing (RT–PCR) positive before 
an event (restricting our analysis to those who never tested positive previously)  
was undertaken.
Day 104 Day 15
90 d
Pre-risk period Clearance Risk-period
14 d 28 d
Date of vaccine
administration Day 28
Fig. 1 | Schematic presentation of the self-controlled case series study 
design. Blue, the control (pre-risk) period: the 90-day period prior to 14 d 
before vaccination (i.e., 15–104 d before vaccine receipt). Green, a 14-day 
clearance period. Orange, the time period from the date of first vaccination 
dose to 28 d after, as the risk (exposed) period.
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We carried out an SCCS analysis including unvaccinated individuals with 
an additional temporal stratification of calendar time to allow for any potential 
secular trends in the outcome. In this analysis, all events in the period from 26 
August 2020 (the date 90 + 14 d before the start of vaccination) were considered. 
Individuals were divided into at-risk versus control periods—that is, those who 
were never vaccinated and vaccinated individuals <14 d before vaccination 
were labeled as unvaccinated. Vaccinated individuals could also be in the 
before-vaccination clearance period or post-vaccination risk period. For this 
analysis, the incidence of events in the vaccine-specific risk period was compared 
to that in the unvaccinated.
Reporting. To minimize the risks of individuals being identified, well-established 
safeguards were in place granting data access only to a limited number of 
accredited investigators, limiting access to identifiable personal information and 
mandating statistical disclosure control policies. For instance, we are unable to 
report results based on five events or fewer or undertake specific case reviews 
of individuals’ data30. We followed the Reporting of Studies Conducted using 
Observational Routinely Collected Data47 and Strengthening the Reporting of 
Observational Studies in Epidemiology48 checklists to guide transparent reporting 
of this cohort study (Supplementary Table 7).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
A data dictionary covering the datasets used in this study can be found at https://
github.com/ EAVE-II/EAVE-II- data-dictionary. The data that support the findings 
of this study are not publicly available because they are based on de-identified 
national clinical records. These are, however, available by application via Scotland’s 
National Safe Haven from Public Health Scotland. The data used in this study can 
be accessed by researchers through NHS Scotland’s Public Benefit and Privacy 
Panel via its Electronic Data Research and Innovation Service49.
Code availability
All code used in this study is publicly available at https://github.com/ EAVE-II/
Covid- vaccine-safety-haemo.
References
 39. Glanz, J. M. et al. Four different study designs to evaluate vaccine safety  
were equally validated with contrasting limitations. J. Clin. Epidemiol. 59, 
808–818 (2006).
 40. National Services Scotland. National Data Catalogue. Rapid Preliminary 
Inpatient Data (RAPID). https://www.ndc.scot.nhs.uk/National-Datasets/data.
asp?SubID=37
 41. Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 
(AZD1222) against SARS-CoV-2: an interim analysis of four randomised 
controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
 42. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 
vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
 43. Paul Ehrlich Institut. COVID-19 Vaccine AstraZeneca—safety assessment 
result: the vaccine is safe and effective in the fight against COVID-19.  
https://www.pei.de/EN/newsroom/hp-news/2021/210319-covid-19-vaccine- 
astrazeneca-safety-assessment-result-vaccine-safe-and-effective.html (2021).
 44. Clift, A. K. et al. Living risk prediction algorithm (QCOVID) for risk of 
hospital admission and mortality from coronavirus 19 in adults: national 
derivation and validation cohort study. Br. Med. J. 371, m3731 (2020).
 45. R Code Team. R: a language and environment for statistical computing. 
https://www.r-project.org/ (R Project for Statistical Computing).
 46. BBC. Oxford–AstraZeneca: EU says ‘no indication’ vaccine linked to clots. 
https://www.bbc.com/news/world-europe-56357760 (2021).
 47. Benchimol, E. I. et al. The REporting of studies Conducted using 
Observational Routinely-collected health Data (RECORD) statement. PLoS 
Med. 12, e1001885 (2015).
 48. von Elm, E. et al. The Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) statement: guidelines for reporting observational 
studies. Int. J. Surg. 12, 1495–1499 (2014).
 49. Public Benefit and Privacy Panel for Health and Social Care. Constitution 
and Terms of Reference. https://www.informationgovernance. scot.nhs.uk/
pbpphsc/ wp-content/uploads/ sites/2/2021/03/ HSC-PBPP-Terms- of- 
Reference- v2.4.pdf (2020).
Acknowledgements
EAVE II is funded by the Medical Research Council (MC_PC_19075) with  
the support of BREATHE: the Health Data Research Hub for Respiratory Health  
(MC_PC_19004), which is funded through the UK Research and Innovation Industrial 
Strategy Challenge Fund and delivered through Health Data Research UK. Additional 
support has been provided through Public Health Scotland and the Community 
Health and Social Care Directorate of the Scottish Government. R.H. acknowledges 
support from the National Institute for Health Research (NIHR) School for Primary 
Care Research, the NIHR Collaboration for Leadership in Applied Health Research 
and Care Oxford and the NIHR Oxford BREATHE Centre. We thank D. Kelly from 
Albasoft Limited for support with making primary care data available and J. Pickett, W. 
Inglis-Humphrey, V. Hammersley, M. Georgiou, L. Brook and L. Gonzalez Rienda for 
support with project management and administration. We thank the EAVE II Public 
Advisory Group. Our thanks to J. Quint, R. Al-Shahi Salman and Q. Hill for their help 
with reviewing code lists. Our thanks also to G. Schiff and L. Smeeth for reviewing this 
work before submission to the UK’s Medicines & Healthcare products Regulatory Agency.
Author contributions
A.S., C.R.S., C.R., L.R., S.V.K. and J.M. conceived this study. C.R.S., A.S., T.S., S.V.K., E.M. 
and C.R. commented on the paper, oversaw the analysis and edited the final manuscript. 
C.R.S., A.S., C.R., T.S. and S.V.K. led the writing of the paper. C.R. and E.M. cleaned and 
analyzed the data. All authors contributed to the study design. All authors contributed 
to drafting the paper and revised the manuscript for important intellectual content. All 
authors gave final approval of the version to be published.
Competing interests
A.S. is a member of the Scottish Government Chief Medical Officer’s COVID-19 
Advisory Group and the New and Emerging Respiratory Virus Threats Risk Stratification 
Subgroup and AstraZeneca’s COVID-19 Thrombocytopenia Task Force; all roles are 
remunerated to A.S. or his institution. C.R.S. declares funding from the Medical Research 
Council, the National Institute for Health Research, the Chief Scientist Office and the 
New Zealand Ministry for Business, Innovation and Employment and Health Research 
Council during the conduct of this study. S.V.K. is co-chair of the Scottish Government’s 
Expert Reference Group on COVID-19 and Ethnicity, is a member of the Scientific 
Advisory Group on Emergencies subgroup on ethnicity and acknowledges funding from 
an NHS Research Scotland Senior Clinical Fellowship, the Medical Research Council and 
the Chief Scientist Office. C.R. is a member of the Scottish Government Chief Medical 
Officer’s COVID-19 Advisory Group, the Scientific Pandemic Influenza Group on 
Modelling and the Medicines & Healthcare products Regulatory Agency’s Vaccine Benefit 
and Risk Working Group. H.R.S. is an advisor to the Scottish Parliament’s COVID-19 
Committee. All other authors report no financial conflicts of interest.
Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41591-021-01408-4.
Supplementary information The online version contains supplementary material 
available at https://doi.org/10.1038/s41591-021-01408-4.
Correspondence and requests for materials should be addressed to A.S.
Peer review information Nature Medicine thanks Eric Topol, Nilanjan Chatterjee and 
the other, anonymous, reviewer(s) for their contribution to the peer review of this work. 
Jennifer Sargent was the primary editor on this article and managed its editorial process 
and peer review in collaboration with the rest of the editorial team.
Reprints and permissions information is available at www.nature.com/reprints.
NATURE MEDICINE | www.nature.com/naturemedicine
ArticlesNature MediciNe
Extended Data Fig. 1 | Vaccine uptake by type of vaccine for individuals in Scotland, up to 10th April 2020 - (a) number by vaccine type, (b) percentage 
of population by vaccine type, and (c) percentage uptake by age and sex. Note: (a) and (b) ChAdOx1 (AZ) or BNT162b2 (PB) vaccines, (c) both 
vaccines. The percentages are based upon the population alive at 8 December 2020. This is derived from the cohort set up on 1 March 2020 by removing 
individuals who died. Individuals in the population who died before vaccination will count in the denominator but cannot count in the numerator and this 
explains the drop off in uptake percentage in the elderly.
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Extended Data Fig. 2 | Number of ITP events per day since September 2019. Note: The line comes from a generalised additive Poisson model fitted 
to the number of cases with a simple spline term for the trend. Graph based upon data up to 22 March 2020. One of the assumptions of the standard 
self-controlled case series analysis is that the underlying rates of the event are constant over time. Fig. S2 shows the number of events for idiopathic 
thrombocytopenic purpura (ITP) since September 2019. A generalised Additive Poisson model was fitted to the daily data with a spline for the number 
of days since 1 September 2019 and a factor for the months. There was no evidence of any seasonal pattern associated with the months of the year 
(p = 0.189, using a change in deviance test) but there was evidence of a non-linear trend (p = 0.0138). Further investigation of the trend was undertaken 
by including binary change in level variables associated with the period post BNT162b2 (8 December 2020) and post ChAdOx1 (5 January 2021) This 
showed that there was no residual increasing trend (p = 0.58), nor any change in level following the introduction of BNT162b2 (p = 0.4315) but there was 
evidence of a change in level amounting to an 0.44 (95% CI 0.20, 0.68; p = 0.0003), additional events per day in the period after the introduction of the 
ChAdOx1 vaccine.
NATURE MEDICINE | www.nature.com/naturemedicine
ArticlesNature MediciNe
Extended Data Fig. 3 | Dates of vaccination and type of vaccine for individuals with an ITP event during the study period. Note: Figure shows when 
individuals with an ITP event were vaccinated. Most received the ChAdOx1 (AZ) rather than the BNT162b2 (PB) vaccine.
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Extended Data Fig. 4 | Data linkage diagram. Note: Community Health Index (CHI) numbers were used to link all datasets. Details on these datasets 
are available in our published protocol (Simpson CR, Robertson C, Vasileiou E, et al. Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 
(EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open 2020;10:e039097. doi: 10.1136/bmjopen-2020-039097) 
There are two core methods of recording vaccine delivery, the national Turas Management Vaccination Tool (TMVT) system and local GP IT systems. 
TMVT was developed as a web application by National Education Scotland (NES). It is in general the preferred method of recording a vaccination where 
this is done outside the normal vaccine locations, predominantly dedicated vaccination centres and community programmes. Most vaccinations delivered 
in general practice settings are recorded in local IT systems; there are a few geographical areas that have however mandated the use of TMVT in every 
setting, including GP practices. Currently GP’s are paid per 100 vaccines administered so they are highly motivated to record information accurately. 
If this is not recorded to a minimum standard, they will not receive payment. All vaccines administered through vaccination centres and community 
programmes are accounted for on a daily basis. All vaccines recorded via TMVT are transferred to the national clinical datastore (NCDS) then to Albasoft 
on a daily basis. At 9 pm each night, these are loaded into a secure database and each practice “polls” the data store as part of the ESCRO data pump 
run between 12:00am and 5:00am each day to request the records for their specific practice. These are then loaded into a local queue at the practice 
for processing later in the day. As part of the same data pump run, the local GP IT system is queried and all vaccination records for the previous day are 
extracted (with a 10 day overlap to catch any retrospective recording) These records are then transferred back to Albasoft and collated into a single 
data source which is returned to the National Clinical Data Store (NCDS) at 8am each morning. As a result, all vaccinations recorded either by TMVT or 
GP IT systems pass through Albasoft in a 24-hour cycle. As part of the agreement to provide these data for EAVE II, vaccination records from both the 
TMVT and GP IT systems are transferred each day following the National Clinical Data Store processing to the EAVE II secure datastore in Public Health 
Scotland (PHS). This ensures that the EAVE II data are as up to date as possible. It is therefore extremely unlikely that any vaccinations will have been 
missed. Prescriptions: Glycoprotein IIb/IIIa inhibitors (tirofiban, abciximab, and eptifibatide), heparin, cephalosporins, linezolid, penicillins, sulphonamides, 
trimethoprim, vancomycin, quinine, ethambutol, rifampicin, carbamazepine, phenytoin, sodium valproate, ibuprofen, naproxen,, amiodarone, furosemide, 
quinidine, thiazides,, haloperidol, paracetamol, irinotecan, mirtazapine, oxaliplatin, salmeterol, tacrolimus and ciprofloxacin (prescription inducing 
thrombocytopenia); oral corticosteroids, intravenous immunoglobulin, azathioprine, ciclosporin, cyclophosphamide, danazol, dapsone, mycophenolate, 
rituximab, vinca alkaloids, eltrombopag, romiplostim (ITS related prescribing).
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